Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
J Autism Dev Disord
; 51(8): 2973, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-33423216
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2021
Tipo del documento:
Article